Literature DB >> 26582961

Humanized Mouse Model of Ebola Virus Disease Mimics the Immune Responses in Human Disease.

Brian H Bird1, Jessica R Spengler1, Ayan K Chakrabarti1, Marina L Khristova2, Tara K Sealy1, JoAnn D Coleman-McCray1, Brock E Martin1, Kimberly A Dodd1, Cynthia S Goldsmith3, Jeanine Sanders3, Sherif R Zaki3, Stuart T Nichol1, Christina F Spiropoulou1.   

Abstract

Animal models recapitulating human Ebola virus disease (EVD) are critical for insights into virus pathogenesis. Ebola virus (EBOV) isolates derived directly from human specimens do not, without adaptation, cause disease in immunocompetent adult rodents. Here, we describe EVD in mice engrafted with human immune cells (hu-BLT). hu-BLT mice developed EVD following wild-type EBOV infection. Infection with high-dose EBOV resulted in rapid, lethal EVD with high viral loads, alterations in key human antiviral immune cytokines and chemokines, and severe histopathologic findings similar to those shown in the limited human postmortem data available. A dose- and donor-dependent clinical course was observed in hu-BLT mice infected with lower doses of either Mayinga (1976) or Makona (2014) isolates derived from human EBOV cases. Engraftment of the human cellular immune system appeared to be essential for the observed virulence, as nonengrafted mice did not support productive EBOV replication or develop lethal disease. hu-BLT mice offer a unique model for investigating the human immune response in EVD and an alternative animal model for EVD pathogenesis studies and therapeutic screening. Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  Ebola virus disease; animal model; cytokine profile; humanized mice; viral hemorrhagic fever; virus pathogenesis

Mesh:

Substances:

Year:  2015        PMID: 26582961      PMCID: PMC4747627          DOI: 10.1093/infdis/jiv538

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  38 in total

Review 1.  Humanized mice for immune system investigation: progress, promise and challenges.

Authors:  Leonard D Shultz; Michael A Brehm; J Victor Garcia-Martinez; Dale L Greiner
Journal:  Nat Rev Immunol       Date:  2012-10-12       Impact factor: 53.106

2.  Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice.

Authors:  Fumihiko Ishikawa; Masaki Yasukawa; Bonnie Lyons; Shuro Yoshida; Toshihiro Miyamoto; Goichi Yoshimoto; Takeshi Watanabe; Koichi Akashi; Leonard D Shultz; Mine Harada
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

3.  Pathogenesis of experimental Ebola virus infection in guinea pigs.

Authors:  B M Connolly; K E Steele; K J Davis; T W Geisbert; W M Kell; N K Jaax; P B Jahrling
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

4.  Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection.

Authors:  F Villinger; P E Rollin; S S Brar; N F Chikkala; J Winter; J B Sundstrom; S R Zaki; R Swanepoel; A A Ansari; C J Peters
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

5.  Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.

Authors:  Nadia Wauquier; Pierre Becquart; Cindy Padilla; Sylvain Baize; Eric M Leroy
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

6.  Humanized mice show clinical signs of dengue fever according to infecting virus genotype.

Authors:  Javier Mota; Rebeca Rico-Hesse
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

7.  Development and characterization of a mouse model for Marburg hemorrhagic fever.

Authors:  Kelly L Warfield; Steven B Bradfute; Jay Wells; Loreen Lofts; Meagan T Cooper; D Anthony Alves; Daniel K Reed; Sean A VanTongeren; Christine A Mech; Sina Bavari
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

8.  Graft versus host disease in the bone marrow, liver and thymus humanized mouse model.

Authors:  Matthew B Greenblatt; Vladimir Vrbanac; Vladimir Vbranac; Trevor Tivey; Kelly Tsang; Andrew M Tager; Antonios O Aliprantis
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

Review 9.  Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers.

Authors:  Victoria Wahl-Jensen; Laura Bollinger; David Safronetz; Fabian de Kok-Mercado; Dana P Scott; Hideki Ebihara
Journal:  Viruses       Date:  2012-12-14       Impact factor: 5.048

Review 10.  Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.

Authors:  Nancy J Sullivan; Julie E Martin; Barney S Graham; Gary J Nabel
Journal:  Nat Rev Microbiol       Date:  2009-05       Impact factor: 60.633

View more
  32 in total

Review 1.  Animal Models of Ebolavirus Infection.

Authors:  Marisa C St Claire; Dan R Ragland; Laura Bollinger; Peter B Jahrling
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

2.  Ebola Virus Replication and Disease Without Immunopathology in Mice Expressing Transgenes to Support Human Myeloid and Lymphoid Cell Engraftment.

Authors:  Jessica R Spengler; Kerry J Lavender; Cynthia Martellaro; Aaron Carmody; Andreas Kurth; James G Keck; Greg Saturday; Dana P Scott; Stuart T Nichol; Kim J Hasenkrug; Christina F Spiropoulou; Heinz Feldmann; Joseph Prescott
Journal:  J Infect Dis       Date:  2016-09-06       Impact factor: 5.226

3.  Gene Therapy with an Adeno-Associated Viral Vector Expressing Human Interleukin-2 Alters Immune System Homeostasis in Humanized Mice.

Authors:  Philip A Durost; Ken-Edwin Aryee; Fatima Manzoor; Roland M Tisch; Christian Mueller; Agata Jurczyk; Leonard D Shultz; Michael A Brehm
Journal:  Hum Gene Ther       Date:  2017-10-03       Impact factor: 5.695

4.  Contribution of Human Lung Parenchyma and Leukocyte Influx to Oxidative Stress and Immune System-Mediated Pathology following Nipah Virus Infection.

Authors:  Olivier Escaffre; Tais B Saito; Terry L Juelich; Tetsuro Ikegami; Jennifer K Smith; David D Perez; Colm Atkins; Corri B Levine; Matthew B Huante; Rebecca J Nusbaum; Janice J Endsley; Alexander N Freiberg; Barry Rockx
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

Review 5.  Human immune system mouse models of Ebola virus infection.

Authors:  Jessica R Spengler; Joseph Prescott; Heinz Feldmann; Christina F Spiropoulou
Journal:  Curr Opin Virol       Date:  2017-08-12       Impact factor: 7.090

6.  A Polymorphism within the Internal Fusion Loop of the Ebola Virus Glycoprotein Modulates Host Cell Entry.

Authors:  Markus Hoffmann; Lisa Crone; Erik Dietzel; Jennifer Paijo; Mariana González-Hernández; Inga Nehlmeier; Ulrich Kalinke; Stephan Becker; Stefan Pöhlmann
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

Review 7.  Filovirus Strategies to Escape Antiviral Responses.

Authors:  Judith Olejnik; Adam J Hume; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler; Elke Mühlberger
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 8.  Organ-on-a-Chip for Cancer and Immune Organs Modeling.

Authors:  Wujin Sun; Zhimin Luo; Junmin Lee; Han-Jun Kim; KangJu Lee; Peyton Tebon; Yudi Feng; Mehmet R Dokmeci; Shiladitya Sengupta; Ali Khademhosseini
Journal:  Adv Healthc Mater       Date:  2019-01-03       Impact factor: 9.933

Review 9.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

10.  Pathogenicity of Ebola and Marburg Viruses Is Associated With Differential Activation of the Myeloid Compartment in Humanized Triple Knockout-Bone Marrow, Liver, and Thymus Mice.

Authors:  Kerry J Lavender; Brandi N Williamson; Greg Saturday; Cynthia Martellaro; Amanda Griffin; Kim J Hasenkrug; Heinz Feldmann; Joseph Prescott
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.